The linked FDA records identify Shockwave Medical, Inc. at 5403 Betsy Ross Drive, Santa Clara, California, as the applicant on P200039, filed August 25, 2020 and approved February 12, 2021 by the Center for Devices and Radiological Health. The approved device is the Shockwave Intravascular Lithotripsy (IVL) System with Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter, assigned product code QMG and reviewed by the Cardiovascular advisory committee. The Summary of Safety and Effectiveness Data states that breakthrough device status was granted on August 19, 2019. The supplied collection holds two linked PMA records, one approval and one 30-day notice, which is a snapshot of the filings provided rather than a measure of company sales or portfolio breadth. [2][4][5]
Documented device and stated indication
The approval record describes the device as indicated for lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting. The same record lists the generic name as Shockwave intravascular lithotripsy system and the device class as 3, with an empty regulation number field. The Summary of Safety and Effectiveness Data identifies the device trade name, product code QMG, applicant address and PMA number P200039, and notes that no panel recommendation dates are listed. [2][4]
The approval letter from the Division of Coronary and Peripheral Intervention Devices confirms the trade name, product code QMG and the August 25, 2020 filing date, and records the February 12, 2021 approval decision. The letter is addressed to a named regulatory affairs specialist at Shockwave Medical, Inc. in Santa Clara, California. [5]
Supplement activity in the linked FDA records
Supplement S025 is recorded as a 30-Day Notice with supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The record states that the change concerned a raw material impurity profile change for the hydrophilic coating at a supplier. It was received August 12, 2026 and decided September 11, 2026 with decision code OK30, and the expedited review flag is marked N. [1]
The supplement record carries the trade name SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH SHOCKWAVE C2/C2+ CORONARY IVL CATHETER and the same product code QMG and Cardiovascular advisory committee as the original approval. The supplied collection counts one OK30 decision and one APPR decision across two linked PMA records; the smaller record sample shows the same one-and-one split. These counts describe the supplied filings only. [1][2]
Naming, brand context and limits of the record
A device listing page lists proprietary names including Shockwave C2, Shockwave C2 Aero Coronary IVL Catheter, Shockwave C2 Aero Fly Coronary IVL Catheter and Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter. A Shockwave product page describes the Shockwave IVL System as enabling calcium modification and links to coronary and peripheral IVL catheter categories. A Shockwave C2+ page carries Johnson and Johnson MedTech branding in its navigation and footer. [7][9][10]
Those company-published pages are the original publishers of the product descriptions and brand presentation; the FDA records establish the applicant identity and filing history. The public documents do not document manufacturing sites beyond the supplier reference in S025, do not state commercial availability by country, and do not provide clinical outcome figures. No recall records appear in the supplied sample. [1][7][9]
